Abstract
Transplants in discordant combinations such as pig-to-man undergo hyperacute rejection (HAR), due to naturally occurring antibodies in human serum. A carbohydrate epitope expressed on pig cells (the Gal(α1,3)Gal epitope) is recognized by these antibodies, which are generated in response to bacteria in the gut [1]. Immune complex formation with this xenoantigen leads to complement activation, cell damage and graft rejection [2].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Abbreviations
- (α1,3)GT:
-
(α1,3)galactosyltransferase
- CRP :
-
complement regulatory protein
- Gal(α1,3)Gal:
-
Galα1-3Galβ1-4GlcNAc-R (α-galactosyl epitope)
- GPI:
-
glycosyl-phosphatidylinositol
- HAR :
-
hyper acute rejection
- PI-PLC :
-
phosphatidylinositol specific phosphlipase C
References
Galili, U., R. E. Mandrell, R. M. Hamadeh, S. B. Shohet, and J. M. Griffiss. 1988. Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun 56, 1730–7.
Platt, J. L., R. J. Fischel, A. J. Matas, S. A. Reif, R. M. Bolman, and F. H. Bach. 1991. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 52, 214–20.
Gustaffson, K., K. Strahan, and A. Preece. 1994. α1, 3Galactosyltransferase: A target for in vivo Genetic Manipulation in Xenotransplantation. Immunological Reviews 141, 59–70.
Galili, U. 1993. Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today 14, 480–2.
Rother, R. R, and S. R Squinto. 1996. The alpha-galactosyl epitope: a sugar coating that makes viruses and cells unpalatable. Cell 86, 185–8.
Takeuchi, Y., C. D. Porter, K. M. Strahan, A. F. Preece, K. Gustafsson, F. L. Cosset, R. A. Weiss, and M. K. Collins. 1996. Sensitization of cells and retroviruses to human serum by (alpha 1–3) galactosyltransferase. Nature 379, 85–8.
Takeuchi, Y., S. H. Liong, P. D. Bieniasz, U. Jäger, C. D. Porter, T. Friedman, M. O. McClure, and R. A. Weiss. 1997. Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by galactosyl(alpha1–3)galactosylation. J Virol 71, 6174–6178.
Morgan, B. P., and S. Meri. 1994. Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 15, 369–96.
Galili, U., and D. LaTemple. 1997. Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol Tod 18, 281–285.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Jäger, U., Takeuchi, Y., Porter, C.D. (1998). Sensitization of Human Cells to Lysis by Human Complement as an Approach for Cancer Gene Therapy. In: Walden, P., Trefzer, U., Sterry, W., Farzaneh, F., Zambon, P. (eds) Gene Therapy of Cancer. Advances in Experimental Medicine and Biology, vol 451. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5357-1_56
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5357-1_56
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7444-2
Online ISBN: 978-1-4615-5357-1
eBook Packages: Springer Book Archive